GSK touts topline win for PD-1 in head-to-head with Keytru­da — while steer­ing next big check­point drug in­to PhI­II

GSK is claim­ing a win for what it calls the largest head-to-head tri­al pit­ting a PD-1 against Mer­ck’s best-sell­ing Keytru­da in a type of lung can­cer, as its Jem­per­li met the pri­ma­ry end­point of ob­jec­tive re­sponse rate.

In a sep­a­rate pos­i­tive move, GSK says it’s mov­ing both arms of the COSTAR Lung tri­al in­to Phase III to test Jem­per­li as well as the TIM-3 in­hibitor cobolimab.

He­s­ham Ab­dul­lah, GSK’s glob­al head of on­col­o­gy de­vel­op­ment, said in a state­ment that the two tri­als “sup­port the am­bi­tion for dostar­limab to be­come the back­bone of our on­go­ing im­muno-on­col­o­gy-based re­search and de­vel­op­ment pro­gramme when used alone and in com­bi­na­tion with stan­dard of care and fu­ture nov­el can­cer ther­a­pies, par­tic­u­lar­ly in pa­tients with cur­rent­ly lim­it­ed treat­ment op­tions.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.